Dr. Laura Jelliffe-Pawlowski serves as faculty in the UCSF School of Medicine and is the Director of Precision Health and Discovery with the UCSF California Preterm Birth Initiative (pretermbirthca.ucsf.edu). She serves as the Primary Investigator for the global HOPE study (hope.ucsf.edu/HOPE_Study) which examines the impact of COVID-19 and pandemic-related hardship on adverse pregnancy and infant outcomes and is the leader and founder of the HOPE Consortium (HOPE.UCSF.edu) which includes investigators from across the US and world whose work focuses on uncovering causes of adverse pregnancy and infant outcomes and identifying in-roads for interventions. She is also a multi-PI on the NIH-funded PROMPT study which focuses on the use of newborn metabolic profile to predict outcomes in babies born very preterm. Dr. Jelliffe-Pawlowski is also the Founder and Chief Scientific Officer of Egg HP which works to provide personalized health information to pregnant women and women trying to become pregnant.
Personalized pregnancy health: Women are their own best experts
The pandemic has shifted the way many us think about pregnancy and precision health. Pregnant women are asking for more transparency and flexibility. They want options - from communication about risk, to how they receive their care, to playing a greater role in planning. Changes are discussed as are new avenues of responsiveness.
Aleksandar Rajkovic, UCSF
Researchers have long been recognizing the uniqueness of women’s health and its substantial effect on clinical practice, acknowledging the increasing appreciation of the importance of multidisciplinary approaches to health and disease. In every organ system, there are diseases that are unique to women, more common in women than in men, or characterized by differences in disease course in women compared to men. This Track will focus on the following topics related to Women’s Health: